Friday December 18, 2020

NASH & Wider Fibrosis Seminar

Overlap and relationships across organ-specific pathological fibrosis, as well as lessons learned from other fibrotic diseases clinical drug development and regulatory intelligence.

Chaired by: Tom Wynn, Vice President, Discovery Inflammation & Immunology, Pfizer

10.00 The Importance of Epigenetic Changes in the Pathogenesis of NASH & Fibrosis

Speaker: Glenn Rosen, Vice President, Preclinical Translational Sciences & Small Molecules, Coherus Biosciences

 

10.20 Keeping up with the Joneses: What Can We Learn From Pulmonary & Cardiac Fibrosis?

Speaker: Lee Borthwick, Fibrosis Biology Lecturer, Newcastle University

 

10.40 Fibrosis & Inflammation: Approaches for Targeting

Speaker: Rugmani Padmanabhan Iyer, Senior Scientist – Cardiovascular, Inflammation & Fibrosis, Merck

 

11.00 Group Q&A & Panel Discussion: What is the Biggest Lesson from Cross-Organ Fibrosis Drug Development that can Inform NASH Candidate Success?

Speakers:

Glenn Rosen, Vice President, Preclinical Translational Sciences & Small Molecules, Coherus Biosciences

Lee Borthwick, Fibrosis Biology Lecturer, Newcastle University

Rugmani Padmanabhan Iyer, Senior Scientist – Cardiovascular, Inflammation & Fibrosis, Merck

 

11.30 Speed Networking

Network exclusively with stakeholders experienced in and prioritizing cross-organ fibrosis research and anti-fibrotic drug development to create fruitful connections and expand your pipeline beyond NASH alone.

 

12.00 Lunch & Networking

 

12.30 How to Cure NASH & Fibrosis: Multi-Targeting Approach?

Speaker: Resat Cinar, Staff Scientist- Laboratory of Physiologic Studies, NIAAA, National Institutes of Health

 

12.50 CORMs: A Single NASH Therapeutic Treating Inflammation, Fibrosis & Metabolic
Stress

Speaker: Jeffrey Wager, Chairman & Chief Executive Officer, Proterris

 

1.10 Next Generation miR-29 Mimics as a Therapy for Pulmonary Fibrosis

Speaker: Rusty Montgomery, Director, Research, Miragen Therapeutics

 

1.30 Group Q&A & Panel Discussion: What is the Biggest Lesson from Cross-Organ Fibrosis Drug Development that can Inform NASH Candidate Success?

Speakers:

Resat Cinar, Staff Scientist- Laboratory of Physiologic Studies, NIAAA, National Institutes of Health

Rusty Montgomery, Director, Research, Miragen Therapeutics

Jeffrey Wager, Chairman & Chief Executive Officer, Proterris

 

2.30 Lessons Learned from Antifibrotic Trials in NASH & Where do we go From Here?

Speaker: Joanne Imperial, Vice President, Clinical Research, Blade Therapeutics

 

2.30 Panel Discussion: Challenges in Anti-Fibrotic Drug Development; Why a Paradigm Shift is Needed

Glenn Rosen, Vice President – Preclinical Translational Sciences & Small Molecules, Coherus Biosciences

Joanne Imperial, Vice President, Clinical Research, Blade Therapeutics

Rugmani Padmanabhan Iyer, Senior Scientist – Cardiovascular, Inflammation & Fibrosis, Merck

 

For all details on each session, please download the full event guide.